Headlands Technologies’s X4 Pharmaceuticals XFOR Stock Holding History

Headlands Technologies’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1	Closed	-$9	–	1587
2024 Q2	$9	Buy	+1	New	+$33	﹤0.01%	1094

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Headlands Technologies's XFOR Position: Q3 2024 in Review

Headlands Technologies sold out of X4 Pharmaceuticals (XFOR) in Q3 2024, closing a stake of 1 share — an estimated $9 sold.

Headlands Technologies first reported a position in XFOR in Q2 2024 and held it in 1 quarter. The position peaked at $9 in Q2 2024. 97 funds tracked by Wall St. Rank hold XFOR as of Q3 2024.

Headlands Technologies reported no remaining X4 Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Headlands Technologies sold 1 X4 Pharmaceuticals share in Q3 2024, an estimated $9.
Headlands Technologies first reported a position in X4 Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Headlands Technologies's X4 Pharmaceuticals position peaked at $9 in Q2 2024.
97 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2024.

Based on Headlands Technologies's 13F filing for Q3 2024, filed 12 Nov 2024.